NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-09
Reading DXR? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Intact: The reason to own it still holds.
Daxor is improving revenue from $11.9M in 2026 to $20.8M in 2027. Losses are shrinking with EPS improving from -$0.21 to -$0.03. The company has stable management and no recent negative news. Its valuation is slightly below peers, offering upside if turnaround succeeds.
Daxor remains unprofitable with negative free cash flow and high risk. Revenue growth is uncertain with only one analyst covering. The stock is volatile and the turnaround may stall or fail.
The price is about 6% above our fair value near $9.8, reflecting modest optimism. The market expects very low growth and continued losses, which matches the cautious outlook.
Breaks if: EPS remains below -$0.10 in FY27
Breaks if: FCF yield remains below -2% over next 4 quarters
Breaks if: revenue falls below $15M in FY27
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
